RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hangzhou Tigermed Consulting Co Stock

Hangzhou Tigermed Consulting Co ROE 2024

Hangzhou Tigermed Consulting Co ROE

0.1

Ticker

300347.SZ

ISIN

CNE100001KV8

In 2024, Hangzhou Tigermed Consulting Co's return on equity (ROE) was 0.1, a -6.02% increase from the 0.1 ROE in the previous year.

Hangzhou Tigermed Consulting Co Aktienanalyse

What does Hangzhou Tigermed Consulting Co do?

Hangzhou Tigermed Consulting Co Ltd is a leading Chinese company in the field of clinical research and medical services. The company was founded in Hangzhou in 2004 and has since experienced rapid development. Today, the company has branches in over 20 countries and employs over 11,000 people worldwide. Hangzhou Tigermed's business model is based on supporting the entire value chain of clinical trials, from planning and execution to statistical analysis and data interpretation. The company works closely with global actors from the pharmaceutical industry, biomedical research institutions, and regulatory authorities to meet international standards for clinical studies. Over the years, Hangzhou Tigermed has expanded its business activities to include various areas such as data management, biostatistics, medical translation, clinical monitoring, drug safety monitoring, and traceability. An important part of Hangzhou Tigermed's business model is the ability to use high-tech platforms and IT systems to enable real-time monitoring and communication during a clinical trial. This allows the company to quickly respond to adverse events and monitor the progress of the study in real-time. The company also offers specialized services, such as the evaluation of oncology studies and the conduct of studies in the field of traditional Chinese medicine. In addition, Hangzhou Tigermed also has its own pharmaceutical research department specializing in the development of innovative drugs. The company has built strong research and development capabilities, with a focus on open innovation projects and partnerships with research institutions and pharmaceutical companies. In collaboration with its industry partners, Hangzhou Tigermed has conducted a number of research projects that have led to significant innovations in medicine. Hangzhou Tigermed also has a strong presence in the international market, particularly in North America and Europe. Through its branches in these regions, the company is able to offer comprehensive collaboration to its customers on a global level. Overall, Hangzhou Tigermed Consulting Co Ltd has established itself as a significant force in the clinical research industry. The company has developed a wide range of services to meet the needs of its customers in the industry. Hangzhou Tigermed's ability to work closely with its customers and adhere to global standards has helped it become a preferred partner for clinical studies and innovative research projects worldwide. Hangzhou Tigermed Consulting Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Hangzhou Tigermed Consulting Co's Return on Equity (ROE)

Hangzhou Tigermed Consulting Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Hangzhou Tigermed Consulting Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Hangzhou Tigermed Consulting Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Hangzhou Tigermed Consulting Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Hangzhou Tigermed Consulting Co stock

What is the ROE (Return on Equity) of Hangzhou Tigermed Consulting Co this year?

The ROE of Hangzhou Tigermed Consulting Co this year is 0.1 undefined.

How has the Return on Equity (ROE) of Hangzhou Tigermed Consulting Co developed compared to the previous year?

The ROE of Hangzhou Tigermed Consulting Co has increased by -6.02% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Hangzhou Tigermed Consulting Co?

A high ROE indicates that Hangzhou Tigermed Consulting Co generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Hangzhou Tigermed Consulting Co?

A low ROE can indicate that Hangzhou Tigermed Consulting Co is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Hangzhou Tigermed Consulting Co affect the company?

A change in ROE (Return on Equity) of Hangzhou Tigermed Consulting Co can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Hangzhou Tigermed Consulting Co?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Hangzhou Tigermed Consulting Co?

Some factors that can influence Hangzhou Tigermed Consulting Co's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Hangzhou Tigermed Consulting Co pay?

Over the past 12 months, Hangzhou Tigermed Consulting Co paid a dividend of 0.55 CNY . This corresponds to a dividend yield of about 1.05 %. For the coming 12 months, Hangzhou Tigermed Consulting Co is expected to pay a dividend of 0.6 CNY.

What is the dividend yield of Hangzhou Tigermed Consulting Co?

The current dividend yield of Hangzhou Tigermed Consulting Co is 1.05 %.

When does Hangzhou Tigermed Consulting Co pay dividends?

Hangzhou Tigermed Consulting Co pays a quarterly dividend. This is distributed in the months of July, June, August, August.

How secure is the dividend of Hangzhou Tigermed Consulting Co?

Hangzhou Tigermed Consulting Co paid dividends every year for the past 14 years.

What is the dividend of Hangzhou Tigermed Consulting Co?

For the upcoming 12 months, dividends amounting to 0.6 CNY are expected. This corresponds to a dividend yield of 1.14 %.

In which sector is Hangzhou Tigermed Consulting Co located?

Hangzhou Tigermed Consulting Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hangzhou Tigermed Consulting Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hangzhou Tigermed Consulting Co from 7/12/2024 amounting to 0.568 CNY, you needed to have the stock in your portfolio before the ex-date on 7/12/2024.

When did Hangzhou Tigermed Consulting Co pay the last dividend?

The last dividend was paid out on 7/12/2024.

What was the dividend of Hangzhou Tigermed Consulting Co in the year 2023?

In the year 2023, Hangzhou Tigermed Consulting Co distributed 0.5 CNY as dividends.

In which currency does Hangzhou Tigermed Consulting Co pay out the dividend?

The dividends of Hangzhou Tigermed Consulting Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hangzhou Tigermed Consulting Co

Our stock analysis for Hangzhou Tigermed Consulting Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hangzhou Tigermed Consulting Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.